Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VNDA stock price vs AEM: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AEM's multiple
Needs AEM P/S.
Implied fair value · at VNDA's multiple
Needs Revenue / share, VNDA P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VNDA FY 2025 (ended Dec 31, 2025) · AEM FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
AGNICO EAGLE MINES LIMITED · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.24x
—
Net debt / EBITDA
Leverage against operating earnings
0.05x
—
Cash and equivalents
Liquid reserves on the balance sheet
$84.85M
$2.87B
Total debt
Interest-bearing obligations outstanding
$78.23M
$4.36B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
VNDA vs SUPN
CATALYST PHARMACEUTICALS, INC.
VNDA vs CPRX
Harmony Biosciences Holdings, Inc.
VNDA vs HRMY
ELI LILLY & Co
VNDA vs LLY
INCYTE CORP
VNDA vs INCY
Sarepta Therapeutics, Inc.
VNDA vs SRPT
NEWMONT Corp /DE/
VNDA vs NEM
BARRICK GOLD CORP
VNDA vs GOLD
FRANCO NEVADA Corp
VNDA vs FNV
ROYAL GOLD INC
VNDA vs RGLD
HECLA MINING CO/DE/
VNDA vs HL
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
